Immatics Misses Revenue and EPS Estimates as Analysts Split

By Amara Osei

What did the quarter show?

Immatics (NASDAQ: IMTX) reported a $0.57 loss per share on Tuesday, $0.08 worse than the $0.49 consensus estimate, as revenue reached $7.84 million against $12.18 million expected.

FiscalAI reported a negative net margin of 495.71% and a negative return on equity of 47.41%. The loss metrics add detail to a quarter in which both revenue and loss per share undershot consensus.

Both headline estimates fell short.

Takeaway: The revenue shortfall and larger-than-expected loss defined the quarter, leaving the next results under greater scrutiny.

How did shares trade?

On Tuesday, IMTX traded down $0.06, or 0.9%, during mid-day trading and reached $6.37. Volume totaled 260,094 shares, below the average of 576,648.

The company’s market capitalization stood at $870.72 million. Its P/E ratio was -3.42 and its beta was 1.38.

The 50-day simple moving average was $7.95, while the 200-day average was $9.48. The 12-month range ran from $6.09 to $12.41.

Takeaway: At $6.37, the shares sat below both moving averages and close to the 12-month low, leaving the earnings miss alongside a weak trading position.

What did research firms say?

Five research actions disclosed a wide range of views:

• Stifel Nicolaus assumed coverage on Tuesday, October 13, with a “buy” rating and a $15.00 price target.
• Wall Street Zen lowered the shares from “hold” to “sell” on Saturday, October 31.
• Weiss Ratings reaffirmed “sell (d-)” on Friday, September 18.
• Mizuho set a $21.00 target price on Thursday, October 29.
• Jefferies Financial Group set a $17.00 target price on Tuesday, August 25.

MarketBeat’s tally showed seven analysts with Buy ratings and one with a Sell rating. It also listed an average rating of “Moderate Buy” and an average price target of $19.00.

The $19.00 MarketBeat average sat above the $15.00 Stifel target and below the $21.00 Mizuho target, while Jefferies’ $17.00 target also fell below that average.

Takeaway: The published targets ranged from $15.00 to $21.00, while MarketBeat’s aggregate rating was “Moderate Buy” and the individual actions diverged.

What did Perceptive Advisors acquire?

An SEC filing disclosed that Immatics director Perceptive Advisors LLC acquired 863,060 shares in a transaction dated Wednesday, August 26. The purchase averaged $8.69 per share and totaled $7,499,991.40.

After the acquisition, Perceptive Advisors owned 11,246,516 shares, which the report valued at $97,732,224.04. The transaction increased its position by 8.31%.

Takeaway: The insider transaction totaled $7,499,991.40 for 863,060 shares and increased Perceptive Advisors’ reported holding by 8.31%.

What does Immatics develop?

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, it uses target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells.

Its pipeline includes two stated treatment formats:

• Engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets.
• TCR bispecific therapies designed to connect T cells with cancer cells.

Takeaway: Immatics is pursuing two TCR-based approaches, but the financial miss and divided research views leave execution under closer scrutiny.